- Coloplast 2Q revenue missed the estimates with DKK6.59 billion marking less than the estimated DKK6.7 billion.
- Ostomy Care revenue also fell short of expectations, with DKK2.28 billion compared to the estimated amount of DKK2.37 billion.
- Continence care revenue was DKK2.06 billion, slightly lower than the estimated DKK2.1 billion.
- Urology care revenue was DKK698 million, which was less than the expected DKK705.5 million.
- Similarly, revenue from emerging markets was less than forecasted, with DKK1.06 billion against the anticipated DKK1.12 billion.
- In contrast, Europe revenue surpassed estimates by scoring DKK3.71 billion compared to the estimated DKK3.67 billion.
- The revenue from other developed markets was higher than forecasted, with DKK1.81 billion versus the assessed DKK1.74 billion.
- Ebitda was on target with the estimate, earning DKK2.11 billion.
- Ebit was DKK1.77 billion, slightly lower than the estimated DKK1.82 billion.
- Coloplast’s net income in 2Q was also less than estimated, scoring DKK1.25 billion against the anticipated DKK1.3 billion.
- The health care company currently has a rating of 9 buys, 15 holds, and 3 sells.
A look at Coloplast A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coloplast A/S, a company specializing in healthcare products and services, has received a mix of Smart Scores indicating its long-term outlook. With a solid Dividend score of 4 and a respectable Momentum score of 4, Coloplast seems to offer a promising investment opportunity for those seeking steady returns and positive market performance. However, its Value and Resilience scores of 2 each suggest potential weaknesses in terms of the company’s valuation and ability to withstand market challenges. The Growth score of 3 indicates moderate potential for expansion in the future. Investors may want to closely monitor these aspects before making investment decisions.
The company’s focus on developing products for various healthcare needs, such as ostomy, incontinence, mastectomy, wound healing, and skin care, positions Coloplast as a key player in the healthcare industry. Collaborating with professional caregivers and user groups for research projects reflects Coloplast’s commitment to innovation and meeting the evolving demands of the market. With a global reach, serving healthcare professionals, dealers, and product users worldwide, Coloplast A/S demonstrates a strong presence in the healthcare sector, potentially offering diverse investment opportunities for interested parties.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
